References
1. Kocheril, S.V., et al., Comparison of disease progression and mortality of connective tissue disease‐related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 2005.53 (4): p. 549-557.
2. Steen, V.D. and T.A. Medsger, Changes in causes of death in systemic sclerosis, 1972–2002. Annals of the rheumatic diseases, 2007.66 (7): p. 940-944.
3. Dekhuijzen, P.N., et al., Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol (1985), 1995. 78 (2): p. 629-37.
4. Fischer, A. and R. Du Bois, Interstitial lung disease in connective tissue disorders. The Lancet, 2012. 380 (9842): p. 689-698.
5. Maltzman, J.S. and G.A. Koretzky, Azathioprine: old drug, new actions. The Journal of clinical investigation, 2003. 111 (8): p. 1122-1124.
6. Strauss, G., W. Osen, and K.M. DEBATIN, Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clinical & Experimental Immunology, 2002.128 (2): p. 255-266.
7. Hall, A. and M. Tilby, Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood reviews, 1992. 6 (3): p. 163-173.
8. Tashkin, D.P., et al., Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Lancet Respir Med, 2016. 4 (9): p. 708-719.
9. Barnes, H., et al., Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev, 2018. 1 (1): p. Cd010908.
10. Oldham, J.M., et al., Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med, 2016. 121 : p. 117-122.
11. Dheda, K., et al., Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clinical rheumatology, 2004. 23 (4): p. 306-309.
12. Poormoghim, H., et al., Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study. Rheumatology international, 2014. 34 (12): p. 1691-1699.
13. Deheinzelin, D., et al., Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. American journal of respiratory and critical care medicine, 1996. 154 (3): p. 794-799.
14. Van Den Hoogen, F., et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis & Rheumatism, 2013. 65 (11): p. 2737-2747.
15. Kay, J. and K.S. Upchurch, ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology, 2012. 51 (suppl_6): p. vi5-vi9.
16. Shiboski, C.H., et al., 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Annals of the rheumatic diseases, 2017. 76 (1): p. 9-16.
17. Lundberg, I.E., et al., 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis & Rheumatology, 2017. 69 (12): p. 2271-2282.
18. Fischer, A., et al., “ERS/ATS Task Force onUndifferentiated Forms of CTD-ILD”. An official European RespiratorySociety/American Thoracic Society research statement: interstitial pneumonia withautoimmunefeatures. 2015.
19. Nishiyama, O., et al., A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J, 2010. 36 (5): p. 1067-72.
20. Society, A.T., Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med, 1995. 152 : p. 185-198.
21. Goh, N.S., et al., Interstitial lung disease in systemic sclerosis: a simple staging system. American journal of respiratory and critical care medicine, 2008. 177 (11): p. 1248-1254.
22. Carter, J.D., et al., An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs.Rheumatology, 2009. 48 (11): p. 1442-1446.
23. Ryerson, C.J., et al., Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest, 2014.145 (4): p. 723-728.
24. Nadashkevich, O., et al., A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clinical rheumatology, 2006. 25 (2): p. 205-212.
25. Tashkin, D.P., et al., Cyclophosphamide versus placebo in scleroderma lung disease. The New England journal of medicine, 2006.354 (25): p. 2655-2666.
26. Fischer, A., et al., Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. The Journal of rheumatology, 2013. 40 (5): p. 640-646.
27. Brito-Zerón, P., et al., Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome. RMD open, 2019. 5 (2): p. e001064-e001064.
28. Parambil, J.G., et al., Interstitial lung disease in primary Sjögren syndrome. Chest, 2006. 130 (5): p. 1489-1495.
29. Roca, F., et al., Interstitial lung disease in primary Sjögren’s syndrome. Autoimmunity reviews, 2017. 16 (1): p. 48-54.
30. Barba, T., et al., Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmunity Reviews, 2019. 18 (2): p. 113-122.
31. Fischer, A., et al., An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. The European respiratory journal, 2015. 46 (4): p. 976-987.
32. Cottin, V. and K.K. Brown, Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory research, 2019. 20 (1): p. 13-13.
Table 1. Demographic and clinical features of azathioprine and cyclophosphamide groups.